Barcelona, Spain
Barcelona, Spain

Time filter

Source Type

Patent
Oryzon Genomics | Date: 2017-02-22

The present invention relates to a compound of Formula 1, wherein: (A) is heteroaryl or aryl; each (A), if present, is independently chosen from aryl, arylalkoxy, arylalkyl, heterocyclyl, aryloxy, halo, alkoxy, haloalkyl, cycloalkyl, haloalkoxy, and cyano, wherein each (A) is substituted with 0, 1, 2, or 3 substituents independently chosen from halo, haloalkyl, haloalkoxy, aryl, arylalkoxy, alkyl, alkoxy, amido, -CH_(2)C(=O)NH_(2), heteroaryl, cyano, sulfonyl, and sulfinyl; X is 0, 1, 2, or 3; (B) is a cyclopropyl ring, wherein (A) and (Z) are covalently bonded to different carbon atoms of (B); (Z) is -NH-; (L) is chosen from a single bond, -CH_(2)-, -CH_(2)CH_(2)-, -CH_(2)CH_(2)CH_(2)-, and -CH_(2)CH_(2)CH_(2)CH_(2)-; and (D) is an aliphatic carbocyclic group or benzocycloalkyl, wherein said aliphatic carbocyclic group or said benzocycloalkyl has 0, 1, 2, or 3 substituents independently chosen from - NH_(2), -NH(C_(1)-C_(6) alkyl), -N(C_(1)-C_(6) alkyl)(C_(1)-C_(6) alkyl), alkyl, halo, amido, cyano, alkoxy, haloalkyl, and haloalkoxy. The compounds of the invention show activity for inhibiting LSD1, which makes them useful in the treatment or prevention of diseases such as cancer.


Grant
Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2011.2.2.2-2 | Award Amount: 3.70M | Year: 2012

The goal of this project is to determine whether the expression of developmental genes in defined subpopulations of DA neurons contributes to the specification of currently unrecognized midbrain DA neuron subtypes and whether their missexpression may contribute to the loss of DA neurons in the adulthood and to the pathogenesis of PD. Many developmental genes have been found to be implicated in the maintenance of midbrain DA neurons at postnatal and adult stages, as assessed by the loss of DA neurons in transgenic mice heterozygous for: Nurr1, Pitx3, FoxA2, en1. On the other hand, genes involved in the pathogenesis of genetic forms of PD, such as Lrkk2 and PINK1, do not cause cell death. In this project we hypothesize that a disregulation of the expression of developmental genes may play a previously unrecognized role in PD. We propose to identify subtypes of midbrain DA neurons at a molecular and functional level in: (i) the developing rodent and human ventral midbrain (VM), (ii) human neural and embryonic stem cell preparations differentiated into midbrain DA neurons, and (iii) DA neurons derived from induced pluripotent stem (iPS) cells generated from control and PD patients.


Patent
Oryzon Genomics | Date: 2014-02-20

The invention relates to methods and compositions for the treatment or prevention of diseases and disorders associated with myeloproliferative disorders. In particular, the invention relates to an LSD 1 inhibitor for use in treating or preventing Philadelphia chromosome negative myeloproliferative disorders.


Patent
Oryzon Genomics | Date: 2016-09-01

The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection.


Patent
Oryzon Genomics | Date: 2016-09-21

The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula I as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection.


The invention relates to methods and compositions for the treatment or prevention of protein conformation disorders. In particular, the invention relates to an LSD1 inhibitor for use in treating or preventing a protein conformation disorder, such as, e.g., Huntington Disease.


The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection. Thus, in one specific aspect the invention relates to formulas (II), (III), (IV), (V), (VI), (VII), (VIII), (IX).


Patent
Oryzon Genomics | Date: 2014-03-27

The present invention relates to a compound of Formula 1, wherein: (A) is heteroaryl or aryl; each (A), if present, is independently chosen from aryl, arylalkoxy, arylalkyl, heterocyclyl, aryloxy, halo, alkoxy, haloalkyl, cycloalkyl, haloalkoxy, and cyano, wherein each (A) is substituted with 0, 1, 2, or 3 substituents independently chosen from halo, haloalkyl, haloalkoxy, aryl, arylalkoxy, alkyl, alkoxy, amido, CH_(2)C(=0)NH_(2), heteroaryl, cyano, sulfonyl, and sulfinyl; X is 0, 1, 2, or 3; (B) is a cyclopropyl ring, wherein (A) and (Z) are covalently bonded to different carbon atoms of (B); (Z) is NH; (L) is chosen from a single bond, CH_(2), CH_(2)CH_(2), CH_(2)CH_(2)CH_(2), and CH_(2)CH_(2)CH_(2)CH_(2); and (D) is an aliphatic carbocyclic group or benzocycloalkyl, wherein said aliphatic carbocyclic group or said benzocycloalkyl has 0, 1, 2, or 3 substituents independently chosen from NH_(2), NH(C_(1)-C_(6 )alkyl), N(C_(1)-C_(6 )alkyl)(C_(1)-C_(6 )alkyl), alkyl, halo, amido, cyano, alkoxy, haloalkyl, and haloalkoxy. (A)X(A)(B)(Z)-(L)-(D) formula (I) The compounds of the invention show activity for inhibiting LSD1, which makes them useful in the treatment or prevention of diseases such as cancer.


Patent
Oryzon Genomics | Date: 2015-02-20

The present invention relates to phenylcyclopropylamine derivatives. In particular, pharmaceutical compositions comprising phenylcyclopropylamine derivatives are provided. The compounds of this invention can, inter alia, be used for the treatment and the prevention of cancer as well as neurodegenerative diseases or disorders.


Patent
Oryzon Genomics | Date: 2015-05-13

The invention relates to cyclopropylamine compounds, in particular the compounds of Formula (I) as described and defined herein, and their use in therapy, including, e.g., the treatment or prevention of cancer.

Loading Oryzon Genomics collaborators
Loading Oryzon Genomics collaborators